2,2'-Dithiodiethanesulfonic acid (BioDeep_00000012973)

   

human metabolite blood metabolite


代谢物信息卡片


2-[(2-Sulphoethyl)disulphanyl]ethane-1-sulphonic acid

化学式: C4H10O6S4 (281.93602400000003)
中文名称: ω,ω-乙二硫二磺酸
谱图信息: 最多检出来源 Homo sapiens(blood) 75%

分子结构信息

SMILES: C(CS(=O)(=O)O)SSCCS(=O)(=O)O
InChI: InChI=1S/C4H10O6S4/c5-13(6,7)3-1-11-12-2-4-14(8,9)10/h1-4H2,(H,5,6,7)(H,8,9,10)

描述信息

D020011 - Protective Agents

同义名列表

18 个代谢物同义名

2-[(2-Sulphoethyl)disulphanyl]ethane-1-sulphonic acid; 2-[(2-sulfoethyl)disulfanyl]ethane-1-sulfonic acid; 2-[(2-Sulphoethyl)disulphanyl]ethane-1-sulphonate; 2-[(2-sulfoethyl)disulfanyl]ethanesulfonic acid; 2,2-Dithiodiethanesulfonic acid, ammonium salt; 2-[(2-Sulfoethyl)disulfanyl]ethane-1-sulfonate; 2,2-Dithiodiethanesulfonic acid, disodium salt; Dimesna (2,2-Dithiodiethanesulfonic acid); Disodium 2,2-dithio-bis-ethane sulfonate; 2,2-Dithiodiethanesulphonic acid; 2,2-Dithiodiethanesulfonic acid; 2,2-Dithiodiethanesulphonate; 2,2-Dithiodiethanesulfonate; Coenzyme M; Tavocept; (S-CoM)2; Dimesna; Coenzyme M disulfide



数据库引用编号

9 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • C J Henry, B K Flesner, S A Bechtel, J N Bryan, D J Tate, K A Selting, J C Lattimer, M E Bryan, L Grubb, F Hausheer. Clinical Evaluation of Tavocept to Decrease Diuresis Time and Volume in Dogs with Bladder Cancer Receiving Cisplatin. Journal of veterinary internal medicine. 2018 Jan; 32(1):370-376. doi: 10.1111/jvim.14848. [PMID: 29080252]
  • Murray J Cutler, Thomas J Velenosi, Ankur Bodalia, Andrew A House, Bradley L Urquhart, David J Freeman. Enzymatic and non-enzymatic mechanisms of dimesna metabolism. Amino acids. 2015 Mar; 47(3):511-23. doi: 10.1007/s00726-014-1882-0. [PMID: 25488427]
  • M J Cutler, B L Urquhart, T J Velenosi, H E Meyer Zu Schwabedissen, G K Dresser, B F Leake, R G Tirona, R B Kim, D J Freeman. In vitro and in vivo assessment of renal drug transporters in the disposition of mesna and dimesna. Journal of clinical pharmacology. 2012 Apr; 52(4):530-42. doi: 10.1177/0091270011400414. [PMID: 21505084]
  • F H Hausheer, D Ding, D Shanmugarajah, B D Leverett, Q Huang, X Chen, H Kochat, P Y Ayala, P N Petluru, A R Parker. Accumulation of BNP7787 in human renal proximal tubule cells. Journal of pharmaceutical sciences. 2011 Sep; 100(9):3977-84. doi: 10.1002/jps.22510. [PMID: 21344411]
  • F H Hausheer, A R Parker, P N Petluru, K W Jair, S Chen, Q Huang, X Chen, P Y Ayala, D Shanmugarajah, H Kochat. Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of human aminopeptidase N. Cancer chemotherapy and pharmacology. 2011 Feb; 67(2):381-91. doi: 10.1007/s00280-010-1333-x. [PMID: 20440617]
  • Frederick H Hausheer, Dakshine Shanmugarajah, Betsy D Leverett, Xinghai Chen, Quili Huang, Harry Kochat, Pavankumar N Petluru, Aulma R Parker. Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of gamma-glutamyl transpeptidase. Cancer chemotherapy and pharmacology. 2010 Apr; 65(5):941-51. doi: 10.1007/s00280-009-1101-y. [PMID: 19714332]
  • Dakshine Shanmugarajah, Daoyuan Ding, Quili Huang, Xinghai Chen, Harry Kochat, Pavankumar N Petluru, Philippe Y Ayala, Aulma R Parker, Frederick H Hausheer. Analysis of BNP7787 thiol-disulfide exchange reactions in phosphate buffer and human plasma using microscale electrochemical high performance liquid chromatography. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2009 Apr; 877(10):857-66. doi: 10.1016/j.jchromb.2009.02.056. [PMID: 19278906]
  • E Boven, M Westerman, C J van Groeningen, M Verschraagen, R Ruijter, I Zegers, W J F van der Vijgh, G Giaccone. Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule. British journal of cancer. 2005 May; 92(9):1636-43. doi: 10.1038/sj.bjc.6602553. [PMID: 15841080]
  • Miranda Verschraagen, Epie Boven, Emine Torun, Frederick H Hausheer, Aalt Bast, Wim J F van der Vijgh. Possible (enzymatic) routes and biological sites for metabolic reduction of BNP7787, a new protector against cisplatin-induced side-effects. Biochemical pharmacology. 2004 Aug; 68(3):493-502. doi: 10.1016/j.bcp.2004.04.005. [PMID: 15242815]
  • M Verschraagen, E Boven, E Torun, C A M Erkelens, F H Hausheer, W J F van der Vijgh. Pharmacokinetic behaviour of the chemoprotectants BNP7787 and mesna after an i.v. bolus injection in rats. British journal of cancer. 2004 Apr; 90(8):1654-9. doi: 10.1038/sj.bjc.6601719. [PMID: 15083199]
  • Miranda Verschraagen, Epie Boven, Rita Ruijter, Kasper van der Born, Johannes Berkhof, Frederick H Hausheer, Wim J F van der Vijgh. Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites. Clinical pharmacology and therapeutics. 2003 Aug; 74(2):157-69. doi: 10.1016/s0009-9236(03)00150-4. [PMID: 12891226]
  • Miranda Verschraagen, Marc A Kedde, Frederick H Hausheer, Wim J F Van Der Vijgh. The chemical reactivity of BNP7787 and its metabolite mesna with the cytostatic agent cisplatin: comparison with the nucleophiles thiosulfate, DDTC, glutathione and its disulfide GSSG. Cancer chemotherapy and pharmacology. 2003 Jun; 51(6):499-504. doi: 10.1007/s00280-003-0610-3. [PMID: 12715205]
  • Miranda Verschraagen, Epie Boven, Ivon Zegers, Frederick H Hausheer, Wim J F Van der Vijgh. Pharmacokinetics of BNP7787 and its metabolite mesna in plasma and ascites: a case report. Cancer chemotherapy and pharmacology. 2003 Jun; 51(6):525-9. doi: 10.1007/s00280-003-0578-z. [PMID: 12750838]
  • Lakshmi Pendyala, Gary Schwartz, Patrick Smith, Joseph Zdanowicz, Michael Murphy, Frederick Hausheer. Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy. Cancer chemotherapy and pharmacology. 2003 May; 51(5):376-84. doi: 10.1007/s00280-003-0587-y. [PMID: 12682786]
  • Miranda Verschraagen, T H Ursula Zwiers, Emine Torun, Martin G Donker, Nico J Reinhoud, Wim J F Van der Vijgh. Simultaneous determination of BNP7787 and its metabolite mesna in plasma and tissue by micro-HPLC with a dual electrochemical detector. Journal of pharmaceutical sciences. 2003 May; 92(5):1040-50. doi: 10.1002/jps.10363. [PMID: 12712424]
  • E Boven, M Verschraagen, T M Hulscher, C A M Erkelens, F H Hausheer, H M Pinedo, W J F van der Vijgh. BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts. European journal of cancer (Oxford, England : 1990). 2002 May; 38(8):1148-56. doi: 10.1016/s0959-8049(02)00036-9. [PMID: 12008205]
  • M Verschraagen, T H Zwiers, P E de Koning, J Welink, W J van der Vijgh. Quantification of BNP7787 (dimesna) and its metabolite mesna in human plasma and urine by high-performance liquid chromatography with electrochemical detection. Journal of chromatography. B, Biomedical sciences and applications. 2001 Apr; 753(2):293-302. doi: 10.1016/s0378-4347(00)00563-6. [PMID: 11334343]
  • F H Hausheer, P Kanter, S Cao, K Haridas, P Seetharamulu, D Reddy, P Petluru, M Zhao, D Murali, J D Saxe, S Yao, N Martinez, A Zukowski, Y M Rustum. Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents. Seminars in oncology. 1998 Oct; 25(5):584-99. doi: NULL. [PMID: 9783598]
  • M P Goren, J M Houle, D A Bush, J T Li, C E Newman, W P Brade. Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjects. Clinical cancer research : an official journal of the American Association for Cancer Research. 1998 Oct; 4(10):2313-20. doi: NULL. [PMID: 9796960]
  • M P Goren, L C Hsu, J T Li. Reduction of dimesna to mesna by the isolated perfused rat liver. Cancer research. 1998 Oct; 58(19):4358-62. doi: NULL. [PMID: 9766664]
  • A el-Yazigi, P Ernst, S al-Rawithi, E Legayada, D A Raines. Pharmacokinetics of mesna and dimesna after simultaneous intravenous bolus and infusion administration in patients undergoing bone marrow transplantation. Journal of clinical pharmacology. 1997 Jul; 37(7):618-24. doi: 10.1002/j.1552-4604.1997.tb04344.x. [PMID: 9243355]
  • V Kurowski, T Wagner. Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy. Cancer chemotherapy and pharmacology. 1997; 39(5):431-9. doi: 10.1007/s002800050594. [PMID: 9054957]
  • M Mohrmann, N Küpper, B Schönfield, M Brandis. Ifosfamide and mesna: effects on the Na/H exchanger activity in renal epithelial cells in culture (LLC-PK1). Renal physiology and biochemistry. 1995 May; 18(3):118-27. doi: 10.1159/000173909. [PMID: 7542792]
  • A el-Yazigi, A Yusuf, S al-Rawithi. Liquid chromatographic analysis of mesna and dimesna in plasma and urine of patients treated with mesna. Therapeutic drug monitoring. 1995 Apr; 17(2):153-8. doi: 10.1097/00007691-199504000-00009. [PMID: 7624904]
  • M Mohrmann, S Ansorge, B Schönfeld, M Brandis. Dithio-bis-mercaptoethanesulphonate (DIMESNA) does not prevent cellular damage by metabolites of ifosfamide and cyclophosphamide in LLC-PK1 cells. Pediatric nephrology (Berlin, Germany). 1994 Aug; 8(4):458-65. doi: 10.1007/bf00856531. [PMID: 7524598]
  • F Pea, M Mazzo, P A Miglioli, E Casiglia, A Pessina, V Moretti. Serum concentrations of sodium 2-mercaptoethanesulfonate (MESNA) and its metabolite, disulfide form (DIMESNA), in volunteers after oral dosing: a comparison between MESNA and ARGIMESNA. Pharmacological research. 1992 Feb; 25 Suppl 1(?):85-6. doi: 10.1016/1043-6618(92)90552-m. [PMID: 1508821]
  • O R Leeuwenkamp, J P Neijt, W J van der Vijgh, H M Pinedo. Reaction kinetics of cisplatin and its monoaquated species with the modulating agents (di)mesna and thiosulphate. European journal of cancer (Oxford, England : 1990). 1991; 27(10):1243-7. doi: 10.1016/0277-5379(91)90090-z. [PMID: 1835593]
  • O R Leeuwenkamp, W J van der Vijgh, J P Neijt, H M Pinedo. Reaction kinetics of cisplatin and its monoaquated species with the (potential) renal protecting agents (di)mesna and thiosulfate. Estimation of the effect of protecting agents on the plasma and peritoneal AUCs of CDDP. Cancer chemotherapy and pharmacology. 1990; 27(2):111-4. doi: 10.1007/bf00689093. [PMID: 2174306]
  • I C Shaw, M S Weeks. Excretion of disodium bis-2-mercaptoethanesulphonate (dimesna) in the urine of volunteers after oral dosing. European journal of cancer & clinical oncology. 1987 Jul; 23(7):933-5. doi: 10.1016/0277-5379(87)90338-5. [PMID: 3117563]
  • C A James, T G Mant, H J Rogers. Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects. British journal of clinical pharmacology. 1987 May; 23(5):561-8. doi: 10.1111/j.1365-2125.1987.tb03092.x. [PMID: 3109461]
  • C A James, H J Rogers. Estimation of mesna and dimesna in plasma and urine by high-performance liquid chromatography with electrochemical detection. Journal of chromatography. 1986 Oct; 382(?):394-8. doi: 10.1016/s0378-4347(00)83550-1. [PMID: 3097045]
  • H Reuther, M Kohl, D B Wildenauer. The interactions of mesna and dimesna with the sulfate exchange in human red blood cells. Arzneimittel-Forschung. 1986 Apr; 36(4):763-5. doi: NULL. [PMID: 3087373]
  • I C Shaw, M I Graham, M S Jones. The fate of [14C]-mesna in the rat. Arzneimittel-Forschung. 1986 Mar; 36(3):487-9. doi: NULL. [PMID: 3085684]
  • N Brock, J Pohl. Prevention of urotoxic side effects by regional detoxification with increased selectivity of oxazaphosphorine cytostatics. IARC scientific publications. 1986; ?(78):269-79. doi: NULL. [PMID: 3108156]
  • I Ikeuchi, T Amano. Simultaneous determination of 2-mercaptoethanesulfonate and its disulfide in human urine by isotachophoresis. Chemical & pharmaceutical bulletin. 1985 Jul; 33(7):3016-9. doi: 10.1248/cpb.33.3016. [PMID: 3936628]
  • K Ormstad, N Uehara. Renal transport and disposition of Na-2-mercaptoethane sulfonate disulfide (dimesna) in the rat. FEBS letters. 1982 Dec; 150(2):354-8. doi: 10.1016/0014-5793(82)80767-9. [PMID: 6819161]
  • N Brock, J Stekar. [Prevention of urotoxic actions of cyclophosphamide and ifosfamide by dimesna (preliminary communication) (author's transl)]. Arzneimittel-Forschung. 1982; 32(5):486-7. doi: NULL. [PMID: 6809014]